What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
David Liew drdavidliew
3 years 6 months ago
and if we don't act, we leave it to the wild, wild west of the private market:
- designed for profit (not necessarily bad)
- but often at the cost of robust dedication to patient outcomes (always bad)
#EULAR2022 @RheumNow https://t.co/zfJWTZ3I1G
David Liew drdavidliew
3 years 6 months ago
In fact, in some select situations we can get by very well without seeing our patient at all?
#EULAR2022 @RheumNow https://t.co/4qcaj2KR9B
David Liew drdavidliew
3 years 6 months ago
So maybe telemedicine can bring us the efficiency that we badly need. In rheumatology, we're drowning in demand - is telemedicine part of the solution?
#EULAR2022 @RheumNow https://t.co/kHBIYRIvBA
Ashima Makol MD AshimaMakol
3 years 6 months ago
✨ Inflammatory #Myositis✨
👉 Excellent summary of Autoantibodies, Immune alterations and Distinct Phenotypes by Dr. Lisa Rider
#EULAR2022 https://t.co/KLzmLUGk9Z
Dr. John Cush RheumNow
3 years 6 months ago
Watch: New 2022 EULAR RA Treatment Guidelines
https://t.co/mF4cKJLtbr
#EULAR2022 https://t.co/oI8p6gL0Tf
Richard Conway RichardPAConway
3 years 6 months ago
Teng et al BLISS-BELIEVE Biomarker outcome RCT Sequential belimumab-rituximab in SLE. Certainly appears to be a serologic benefit on dsDNA, C3/4. But we need clinical parameters to correlate with this. @RheumNow #EULAR2022 OP0281 https://t.co/iEeSN0SNcr https://t.co/HN8ya4QZLU
Richard Conway RichardPAConway
3 years 6 months ago
Manzi et al. Data on anifrolumab from TULIP studies on depression/suicidality. No effect. @RheumNow #EULAR2022 OP0282 https://t.co/5n7HBqzLkX https://t.co/fq4dxskJaA
Dr. Antoni Chan synovialjoints
3 years 6 months ago
Roberto Giacomeilli from Italy explaining the mechanisms on how COVID-19 may cause rheumatic disease #EULAR2022 @RheumNow https://t.co/a2kTT7vcRx
Richard Conway RichardPAConway
3 years 6 months ago
Nossent et al Hospitalisation with opportunistic infection twice as high in RA vs AxSpA/PsA. Has IMPROVED over biologic era. To me, suggests benefits of proper disease control on infection risk
@RheumNow
#EULAR2022 OP0274 https://t.co/cqUoRti4We https://t.co/Ozz7jH3z4N
Dr. Antoni Chan synovialjoints
3 years 6 months ago
Catching up with Jack, a great teacher and educator @RheumNow #rheum #rheumedu #EULAR2022 https://t.co/2wqbhpIb2P
Dr. Rachel Tate uptoTate
3 years 6 months ago
LDA/MDA achieved in 60% of PsA pts on (mostly) bDMARDs. Combo baseline features: TJC>3, SJC>5, CRP>10 mg/l, HAQ>0.5, enthesitis, dactylitis, BMI>30 & sDMARDs tx constitutes negative predictive impact on MDA/LDA after 1 yr. #EULAR2022 POS0080 @RheumNow https://t.co/PugwiuSMPm https://t.co/nqadEjA3Xe
Robert B Chao, MD doctorRBC
3 years 6 months ago
Izokibep - potent and small molecule IL-17A inhibitor Phase 2 study in PsA patients
Fast onset, met ACR50 primary endpoint
AE included site reaction and candida infection
@RheumNow #EULAR2022 ABST#OP0258 https://t.co/vZ4xmnhyhl
David Liew drdavidliew
3 years 6 months ago
I could listen to Dennis McGonagle talk about enthesitis all day.
If you missed it, one to check out later #EULAR2022 @RheumNow https://t.co/8pRKqMB06j
Dr. Rachel Tate uptoTate
3 years 6 months ago
Add on MTX does not impair UST immunogenicity in PsA. #EULAR2022 POS0079 @RheumNow
https://t.co/CalEn7KpsX https://t.co/NZUqdX0XKo
Robert B Chao, MD doctorRBC
3 years 6 months ago
52 wk trial using MSK Ultrasound study on PsA receiving secukinumab showed an early and continued improvement in GLOESS scores.
Synovial hypertrophy most responsive.
Hands and feet, wrist and knees most affected and responsive.
@RheumNow #EULAR2022 ABST#OP0260 https://t.co/jeQezIWLxa
Poster Hall